Yes we are all a bit riled up by this. It is hard not to believe we are sitting on the precipice of really REALY good news: (1) DVAX-L Approval for Mesenchyma Subgroup patients (at minimum) (2) Joint new trial with Merck & BMS for DVAX with PDL1 inhibiots Again HEE HA . . . HIP HIP . . . Fasten your seat-belt Dorothea cause Kansas is about to go bye-bye